RO3

RO3 is a selective antagonist of homomeric P2X3 and heteromeric P2X2/3 receptor

Bufuralol (Ro 3-4787) is an orally active β-adrenergic receptor blocker with a certain degree of sympathomimetic effects and can be used to study cardiovascular diseases.

RO3244794 is a selective prostacyclin (IP) receptor antagonist that can be used to study liver injury.

Ro3280 (Ro5203280) is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).

RO320-2947/001 is a bioactive chemical.

TO-PRO3 iodide is a nucleic acid stain that can stain the nucleus of cells in different states, including living, early apoptotic, and necrotic cells.

RO314724 is a HDAC inhibitor. RO314724 is also a a reversible, tightly binding, MMP inhibitor with a Ki of 26 nm. Matrix metalloproteinases (MMPs) belong to the key enzymes of the proteolytic destruction of cartilage matrix during chronic rheumatic diseases. Ro314724 displayed MMP-proteoglycanase inhibitory activity both in vitro and ex vivo and proved to be not harmful to the morphology, viability and proteoglycan biosynthesis of bovine articular cartilage explants.

[Leu31,Pro34]-Neuropeptide Y(human,rat) TFA acts as a specific agonist for the neuropeptide Y Y1 receptor and also activates Y4 and Y5 receptors, elevating blood pressure in anesthetized rats and enhancing food intake [1] [2].

(Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is a stable and specific full agonist for the human GIP receptor (hGIPR) with a high binding affinity (K i / K d values of 0.90 nM), demonstrating efficacy in targeting hGIPR, and is thus suitable for obesity-related diabetes research [1] [2].

(Pro3) GIP, human acetate (299898-52-5 Free base) is a potent, stable, and specific full agonist peptide for the human GIP receptor (GIPR). (Pro3) GIP, human acetate (299898-52-5 Free base) is the acetate salt form of a modified analog of natural GIP in which three alanine (Ala) residues have been mutated to proline (Pro). (Pro3) GIP, human acetate (299898-52-5 Free base) is a glucose-dependent insulin secretion (GIP) agonist and a weak inhibitor of gastric acid secretion.

(Pro34)-Peptide YY (human) is a highly Y1-selective full agonist of Peptide YY/neuropeptide Y receptors [1].

(Leu31,Pro34)-Peptide YY (human) is a derivative of Peptide YY that acts as a potent and selective Y1 receptor agonist, with a dissociation constant (KD) of 1.0 nM [1].

"(Leu31,Pro34)-Peptide YY (human) (TFA) is the trifluoroacetic acid (TFA) form of (Leu31,Pro34)-Peptide YY (human), a derivative of Peptide YY that acts as a potent and selective Y1 agonist, exhibiting a dissociation constant (K D) of 1.0 nM [1]."

[D-Phe2,6, Pro3]-LH-RH is a potent antagonist of luteinizing hormone-releasing hormone (LHRH).

High affinity neuropeptide Y Y1 receptor agonist (Ki = 0.39 nM). Also shows affinity for Y4 and Y5 receptors.

GIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insul

[Pro3]-GIP (Mouse) acetate is mouse [Pro3]-GIP. [Pro3]-GIP is a GIP receptor antagonist.

High affinity rat GIP receptor partial agonist (Kd = 13 nM). Increases cAMP accumulation in COS-7 cells transfected with rat GIP receptor, while also acting as a competitive antagonist of GIP.

High affinity neuropeptide Y Y1 receptor agonist

[Pro34]Neuropeptide Y, porcine functions as a selective agonist for the NPY (Y1) receptor and induces vasoconstriction in the guinea pig's caval vein [1].

RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.

Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.

Bemcentinib (R428) belongs to small molecule inhibitors and is a highly selective oral Axl inhibitor (IC50 = 14 nM) with oral bioavailability and potent cell permeability. This compound effectively inhibits cancer cell migration and invasion, blocks tumor dissemination, and prolongs survival in various tumor models.

TNF-α agonistic 1, a TNF-α agonistic compound, could induce cells to secrete TNF- α.